Christopher Gignoux
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetics, Population | 33 | 2025 | 214 | 3.300 |
Why?
| | Genome-Wide Association Study | 42 | 2025 | 1431 | 2.200 |
Why?
| | Polymorphism, Single Nucleotide | 55 | 2025 | 2189 | 2.080 |
Why?
| | Genome, Human | 25 | 2025 | 425 | 1.930 |
Why?
| | Genetic Variation | 18 | 2025 | 991 | 1.710 |
Why?
| | Genetic Predisposition to Disease | 27 | 2025 | 2426 | 1.450 |
Why?
| | Genomics | 19 | 2025 | 795 | 1.210 |
Why?
| | Models, Genetic | 12 | 2025 | 600 | 1.180 |
Why?
| | Multifactorial Inheritance | 11 | 2025 | 174 | 1.040 |
Why?
| | Precision Medicine | 4 | 2024 | 429 | 0.970 |
Why?
| | Asthma | 19 | 2019 | 2295 | 0.960 |
Why?
| | Haplotypes | 23 | 2025 | 494 | 0.950 |
Why?
| | Genetics, Medical | 5 | 2023 | 26 | 0.900 |
Why?
| | Biological Specimen Banks | 5 | 2024 | 102 | 0.780 |
Why?
| | Pharmacogenetics | 2 | 2021 | 180 | 0.770 |
Why?
| | Transcriptome | 5 | 2024 | 971 | 0.760 |
Why?
| | Gastritis | 1 | 2023 | 108 | 0.740 |
Why?
| | Enteritis | 1 | 2023 | 103 | 0.740 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.700 |
Why?
| | Human Migration | 6 | 2021 | 22 | 0.640 |
Why?
| | Gene Flow | 8 | 2020 | 86 | 0.600 |
Why?
| | Humans | 131 | 2025 | 137585 | 0.600 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 10 | 0.600 |
Why?
| | Smad2 Protein | 1 | 2018 | 38 | 0.590 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 325 | 0.590 |
Why?
| | Genotype | 24 | 2025 | 1916 | 0.580 |
Why?
| | Gene Frequency | 13 | 2025 | 521 | 0.570 |
Why?
| | Pedigree | 4 | 2025 | 514 | 0.550 |
Why?
| | Chromosome Mapping | 11 | 2023 | 523 | 0.480 |
Why?
| | Population | 2 | 2014 | 35 | 0.470 |
Why?
| | Population Growth | 2 | 2012 | 9 | 0.460 |
Why?
| | DNA, Mitochondrial | 6 | 2016 | 200 | 0.460 |
Why?
| | Metagenomics | 4 | 2023 | 169 | 0.440 |
Why?
| | DNA Methylation | 4 | 2025 | 643 | 0.430 |
Why?
| | Receptors, KIR | 5 | 2022 | 98 | 0.420 |
Why?
| | Indians, North American | 7 | 2021 | 643 | 0.420 |
Why?
| | Mexican Americans | 7 | 2023 | 120 | 0.410 |
Why?
| | Evolution, Molecular | 6 | 2021 | 493 | 0.400 |
Why?
| | Agriculture | 2 | 2011 | 103 | 0.400 |
Why?
| | Genetic Loci | 7 | 2019 | 288 | 0.370 |
Why?
| | Exome | 5 | 2022 | 231 | 0.370 |
Why?
| | Phenotype | 14 | 2025 | 3196 | 0.340 |
Why?
| | Molecular Epidemiology | 3 | 2023 | 68 | 0.340 |
Why?
| | Thyroid Neoplasms | 2 | 2025 | 343 | 0.340 |
Why?
| | Alleles | 12 | 2025 | 891 | 0.340 |
Why?
| | Quantitative Trait Loci | 6 | 2024 | 380 | 0.340 |
Why?
| | Indians, South American | 2 | 2020 | 25 | 0.340 |
Why?
| | Genetic Association Studies | 3 | 2022 | 377 | 0.320 |
Why?
| | Computational Biology | 3 | 2023 | 644 | 0.310 |
Why?
| | Population Groups | 2 | 2020 | 62 | 0.310 |
Why?
| | Female | 51 | 2025 | 73304 | 0.310 |
Why?
| | Linkage Disequilibrium | 9 | 2023 | 268 | 0.300 |
Why?
| | Proteome | 2 | 2024 | 472 | 0.290 |
Why?
| | Kidney Diseases | 2 | 2025 | 408 | 0.280 |
Why?
| | Skin Pigmentation | 2 | 2018 | 49 | 0.280 |
Why?
| | Selection, Genetic | 4 | 2019 | 273 | 0.270 |
Why?
| | Receptors, KIR2DL1 | 2 | 2018 | 19 | 0.260 |
Why?
| | Male | 48 | 2025 | 67762 | 0.260 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 192 | 0.260 |
Why?
| | Epigenesis, Genetic | 4 | 2025 | 660 | 0.260 |
Why?
| | Genetic Markers | 7 | 2023 | 344 | 0.260 |
Why?
| | Mexico | 8 | 2023 | 225 | 0.260 |
Why?
| | Phylogeography | 5 | 2020 | 54 | 0.250 |
Why?
| | Environmental Exposure | 3 | 2017 | 579 | 0.250 |
Why?
| | Colorado | 4 | 2024 | 4565 | 0.250 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.240 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 17 | 0.240 |
Why?
| | Minority Groups | 2 | 2019 | 266 | 0.240 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 39 | 0.240 |
Why?
| | Risk Factors | 17 | 2025 | 10388 | 0.240 |
Why?
| | Obesity | 3 | 2025 | 2992 | 0.240 |
Why?
| | Delivery of Health Care | 2 | 2023 | 951 | 0.230 |
Why?
| | Algorithms | 4 | 2025 | 1704 | 0.230 |
Why?
| | Phylogeny | 7 | 2022 | 904 | 0.230 |
Why?
| | Puerto Rico | 8 | 2021 | 53 | 0.220 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1774 | 0.220 |
Why?
| | Bivalvia | 1 | 2024 | 8 | 0.220 |
Why?
| | Killer Cells, Natural | 4 | 2021 | 449 | 0.220 |
Why?
| | Heterozygote | 3 | 2021 | 293 | 0.220 |
Why?
| | Longevity | 1 | 2025 | 165 | 0.210 |
Why?
| | Chromosomes, Human, Pair 6 | 3 | 2014 | 52 | 0.210 |
Why?
| | Genes, MHC Class I | 2 | 2021 | 35 | 0.210 |
Why?
| | Thyroid Nodule | 1 | 2024 | 56 | 0.200 |
Why?
| | Long QT Syndrome | 1 | 2024 | 70 | 0.200 |
Why?
| | Young Adult | 12 | 2022 | 13209 | 0.200 |
Why?
| | Glaucoma, Open-Angle | 1 | 2024 | 103 | 0.190 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 6 | 0.190 |
Why?
| | Proteins | 2 | 2022 | 1009 | 0.190 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 18 | 0.190 |
Why?
| | Software | 2 | 2025 | 665 | 0.190 |
Why?
| | Emigration and Immigration | 3 | 2013 | 46 | 0.190 |
Why?
| | Case-Control Studies | 10 | 2024 | 3556 | 0.190 |
Why?
| | Immunoglobulin E | 2 | 2014 | 342 | 0.190 |
Why?
| | Myocardial Ischemia | 1 | 2023 | 263 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2024 | 410 | 0.180 |
Why?
| | Demography | 5 | 2018 | 291 | 0.180 |
Why?
| | Jews | 1 | 2021 | 23 | 0.180 |
Why?
| | Obesity, Morbid | 1 | 2025 | 264 | 0.180 |
Why?
| | Collagen Type VII | 1 | 2021 | 28 | 0.180 |
Why?
| | Computer Simulation | 6 | 2025 | 978 | 0.180 |
Why?
| | Cardiovascular Diseases | 2 | 2025 | 2111 | 0.180 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.180 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 41 | 0.180 |
Why?
| | History, Medieval | 3 | 2021 | 47 | 0.180 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 37 | 0.180 |
Why?
| | Electrocardiography | 1 | 2024 | 629 | 0.170 |
Why?
| | Drug Implants | 1 | 2021 | 82 | 0.170 |
Why?
| | Aged | 13 | 2025 | 23961 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 778 | 0.170 |
Why?
| | Indians, Central American | 1 | 2020 | 6 | 0.170 |
Why?
| | Eosinophilia | 1 | 2023 | 218 | 0.170 |
Why?
| | Latin America | 2 | 2018 | 93 | 0.170 |
Why?
| | Adiposity | 1 | 2025 | 518 | 0.170 |
Why?
| | Population Health | 1 | 2021 | 47 | 0.170 |
Why?
| | Adult | 19 | 2025 | 37929 | 0.160 |
Why?
| | Adolescent | 18 | 2021 | 21513 | 0.160 |
Why?
| | Reference Standards | 1 | 2020 | 186 | 0.160 |
Why?
| | Self Report | 2 | 2021 | 827 | 0.160 |
Why?
| | Pre-Eclampsia | 1 | 2022 | 190 | 0.160 |
Why?
| | Adaptation, Biological | 1 | 2020 | 56 | 0.160 |
Why?
| | Lipase | 1 | 2020 | 69 | 0.160 |
Why?
| | Human Genetics | 1 | 2019 | 3 | 0.160 |
Why?
| | Triglycerides | 2 | 2023 | 524 | 0.160 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 363 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 2531 | 0.150 |
Why?
| | United States | 16 | 2025 | 14841 | 0.150 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 351 | 0.150 |
Why?
| | Apolipoprotein L1 | 1 | 2018 | 14 | 0.150 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 767 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 24 | 0.150 |
Why?
| | Antiporters | 1 | 2018 | 22 | 0.150 |
Why?
| | United Kingdom | 3 | 2025 | 318 | 0.150 |
Why?
| | Europe | 5 | 2020 | 414 | 0.150 |
Why?
| | Coronary Artery Disease | 2 | 2023 | 698 | 0.150 |
Why?
| | Liver Diseases | 1 | 2021 | 315 | 0.150 |
Why?
| | Chromosomes, Human, Y | 2 | 2008 | 24 | 0.140 |
Why?
| | HLA-C Antigens | 1 | 2018 | 35 | 0.140 |
Why?
| | Primates | 1 | 2019 | 126 | 0.140 |
Why?
| | Collagen Diseases | 1 | 2017 | 6 | 0.140 |
Why?
| | Fibrillar Collagens | 1 | 2017 | 13 | 0.140 |
Why?
| | Atherosclerosis | 1 | 2022 | 415 | 0.140 |
Why?
| | Dermatitis, Atopic | 1 | 2021 | 329 | 0.140 |
Why?
| | Middle Aged | 15 | 2025 | 33479 | 0.140 |
Why?
| | Epistasis, Genetic | 1 | 2017 | 70 | 0.140 |
Why?
| | Weight Gain | 1 | 2021 | 519 | 0.140 |
Why?
| | Microbiota | 2 | 2023 | 762 | 0.140 |
Why?
| | Apolipoprotein A-V | 1 | 2017 | 3 | 0.140 |
Why?
| | Gene Pool | 2 | 2013 | 5 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2021 | 956 | 0.130 |
Why?
| | History, Ancient | 3 | 2013 | 54 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1468 | 0.130 |
Why?
| | Saliva | 2 | 2020 | 242 | 0.130 |
Why?
| | Inflammation | 2 | 2025 | 2837 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 806 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 279 | 0.130 |
Why?
| | Homozygote | 3 | 2023 | 203 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 372 | 0.130 |
Why?
| | Language | 2 | 2011 | 292 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 806 | 0.120 |
Why?
| | Colombia | 3 | 2021 | 41 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.120 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5472 | 0.110 |
Why?
| | CpG Islands | 2 | 2025 | 157 | 0.110 |
Why?
| | Social Class | 2 | 2013 | 282 | 0.110 |
Why?
| | Genealogy and Heraldry | 1 | 2013 | 5 | 0.110 |
Why?
| | Premature Birth | 1 | 2018 | 333 | 0.110 |
Why?
| | Africa, Southern | 3 | 2018 | 8 | 0.110 |
Why?
| | Minority Health | 1 | 2013 | 20 | 0.110 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 24 | 0.110 |
Why?
| | Health Surveys | 1 | 2016 | 514 | 0.110 |
Why?
| | Population Dynamics | 2 | 2012 | 151 | 0.100 |
Why?
| | Urban Health | 1 | 2013 | 92 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.100 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 136 | 0.100 |
Why?
| | Search Engine | 1 | 2013 | 12 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1164 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.100 |
Why?
| | Nasal Mucosa | 1 | 2014 | 107 | 0.100 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 44 | 0.100 |
Why?
| | Albuterol | 1 | 2013 | 110 | 0.100 |
Why?
| | Neanderthals | 1 | 2013 | 13 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 422 | 0.100 |
Why?
| | Child | 15 | 2020 | 21935 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2012 | 25 | 0.100 |
Why?
| | Kallikreins | 1 | 2012 | 29 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2013 | 195 | 0.100 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 63 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2013 | 531 | 0.100 |
Why?
| | Mutation | 5 | 2018 | 3958 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2017 | 771 | 0.100 |
Why?
| | Air Pollution | 1 | 2016 | 316 | 0.100 |
Why?
| | Biological Evolution | 2 | 2019 | 474 | 0.090 |
Why?
| | Respiratory Function Tests | 2 | 2012 | 600 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 162 | 0.090 |
Why?
| | Bronchodilator Agents | 1 | 2013 | 252 | 0.090 |
Why?
| | HLA-B Antigens | 2 | 2022 | 62 | 0.090 |
Why?
| | Tuberculosis | 1 | 2014 | 279 | 0.090 |
Why?
| | History, 17th Century | 1 | 2011 | 16 | 0.090 |
Why?
| | History, 15th Century | 1 | 2011 | 12 | 0.090 |
Why?
| | Polynesia | 2 | 2021 | 4 | 0.090 |
Why?
| | History, 18th Century | 1 | 2011 | 19 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 314 | 0.090 |
Why?
| | Lung | 2 | 2016 | 4060 | 0.090 |
Why?
| | Cluster Analysis | 3 | 2023 | 499 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 60 | 0.090 |
Why?
| | Anthropometry | 2 | 2025 | 213 | 0.090 |
Why?
| | Chile | 2 | 2021 | 24 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2014 | 2253 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2011 | 125 | 0.090 |
Why?
| | Body Height | 2 | 2023 | 199 | 0.090 |
Why?
| | Estrogen Receptor alpha | 1 | 2012 | 145 | 0.080 |
Why?
| | Body Mass Index | 3 | 2025 | 2389 | 0.080 |
Why?
| | History, 21st Century | 1 | 2011 | 213 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 283 | 0.080 |
Why?
| | Databases, Genetic | 2 | 2021 | 237 | 0.080 |
Why?
| | South Africa | 3 | 2015 | 222 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 325 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2020 | 75 | 0.080 |
Why?
| | Peru | 2 | 2022 | 58 | 0.080 |
Why?
| | Vital Capacity | 1 | 2010 | 311 | 0.080 |
Why?
| | Electronic Health Records | 3 | 2021 | 1069 | 0.080 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2019 | 36 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1396 | 0.070 |
Why?
| | Africa | 3 | 2017 | 108 | 0.070 |
Why?
| | South America | 2 | 2020 | 60 | 0.070 |
Why?
| | Americas | 2 | 2018 | 28 | 0.070 |
Why?
| | Life Style | 2 | 2022 | 490 | 0.070 |
Why?
| | Signal Transduction | 2 | 2019 | 5079 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1040 | 0.070 |
Why?
| | Risk | 3 | 2018 | 912 | 0.070 |
Why?
| | Ants | 1 | 2007 | 25 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2024 | 405 | 0.070 |
Why?
| | Linguistics | 1 | 2007 | 27 | 0.070 |
Why?
| | Odds Ratio | 3 | 2014 | 1070 | 0.070 |
Why?
| | Whole Genome Sequencing | 2 | 2018 | 160 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2019 | 55 | 0.070 |
Why?
| | Speech | 1 | 2007 | 70 | 0.070 |
Why?
| | Human Genome Project | 2 | 2017 | 15 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 36 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 767 | 0.060 |
Why?
| | Cytokine Receptor gp130 | 1 | 2025 | 12 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3715 | 0.060 |
Why?
| | Receptors, Interleukin-6 | 1 | 2025 | 43 | 0.060 |
Why?
| | Bias | 2 | 2019 | 218 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 539 | 0.060 |
Why?
| | Base Sequence | 3 | 2016 | 2181 | 0.060 |
Why?
| | Body Size | 1 | 2025 | 108 | 0.060 |
Why?
| | RNA | 1 | 2011 | 921 | 0.060 |
Why?
| | Child, Preschool | 6 | 2020 | 11074 | 0.060 |
Why?
| | Phenethylamines | 1 | 2024 | 23 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 167 | 0.060 |
Why?
| | Torsades de Pointes | 1 | 2024 | 24 | 0.060 |
Why?
| | Argentina | 2 | 2015 | 26 | 0.050 |
Why?
| | Microsatellite Repeats | 3 | 2011 | 168 | 0.050 |
Why?
| | Cohort Studies | 4 | 2019 | 5742 | 0.050 |
Why?
| | Prevalence | 2 | 2025 | 2734 | 0.050 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 660 | 0.050 |
Why?
| | Iran | 1 | 2023 | 43 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 76 | 0.050 |
Why?
| | Geography | 2 | 2016 | 200 | 0.050 |
Why?
| | Biology | 1 | 2024 | 88 | 0.050 |
Why?
| | Caribbean Region | 2 | 2013 | 28 | 0.050 |
Why?
| | Lipoprotein(a) | 1 | 2023 | 67 | 0.050 |
Why?
| | Minisatellite Repeats | 1 | 2002 | 42 | 0.050 |
Why?
| | Factor X | 1 | 2022 | 27 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 305 | 0.050 |
Why?
| | Factor VII | 1 | 2022 | 24 | 0.050 |
Why?
| | Genes | 1 | 2002 | 230 | 0.050 |
Why?
| | Blood Coagulation Factors | 1 | 2022 | 54 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 3295 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 115 | 0.050 |
Why?
| | Genome, Viral | 1 | 2022 | 144 | 0.050 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2021 | 45 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 55 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2021 | 46 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2020 | 6079 | 0.040 |
Why?
| | Bronchi | 2 | 2014 | 260 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 455 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 172 | 0.040 |
Why?
| | Central America | 1 | 2020 | 24 | 0.040 |
Why?
| | China | 1 | 2021 | 217 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 669 | 0.040 |
Why?
| | Sulfonamides | 1 | 2024 | 513 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 252 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.040 |
Why?
| | Infant | 3 | 2021 | 9465 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 759 | 0.040 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 21 | 0.040 |
Why?
| | Topography, Medical | 1 | 2019 | 10 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2844 | 0.040 |
Why?
| | Asia, Northern | 1 | 2018 | 1 | 0.040 |
Why?
| | Classification | 1 | 2019 | 21 | 0.040 |
Why?
| | Mongolia | 1 | 2018 | 6 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1946 | 0.040 |
Why?
| | Animals | 6 | 2024 | 36940 | 0.040 |
Why?
| | Databases, Nucleic Acid | 1 | 2018 | 34 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7635 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 64 | 0.040 |
Why?
| | Receptors, Natural Killer Cell | 1 | 2018 | 16 | 0.040 |
Why?
| | Hominidae | 1 | 2019 | 85 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 150 | 0.040 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 71 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 889 | 0.030 |
Why?
| | New York City | 1 | 2017 | 85 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 488 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3284 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 99 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1079 | 0.030 |
Why?
| | DNA | 1 | 2024 | 1459 | 0.030 |
Why?
| | Multigene Family | 1 | 2017 | 198 | 0.030 |
Why?
| | DNA, Intergenic | 1 | 2016 | 26 | 0.030 |
Why?
| | Parents | 1 | 2025 | 1347 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Musculoskeletal Diseases | 1 | 2017 | 78 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 59 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 2900 | 0.030 |
Why?
| | Prospective Studies | 3 | 2014 | 7604 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2475 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2019 | 351 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2019 | 289 | 0.030 |
Why?
| | Sexism | 1 | 2016 | 61 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 664 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2017 | 162 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 934 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 460 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 750 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2607 | 0.030 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2014 | 16 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 21 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2139 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2014 | 137 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 52 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 87 | 0.030 |
Why?
| | HapMap Project | 1 | 2013 | 5 | 0.030 |
Why?
| | Biomarkers | 1 | 2025 | 4149 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 636 | 0.030 |
Why?
| | Africa, Northern | 1 | 2013 | 4 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1570 | 0.030 |
Why?
| | Blood Glucose | 1 | 2023 | 2186 | 0.030 |
Why?
| | Mammography | 1 | 2014 | 154 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1357 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 2071 | 0.030 |
Why?
| | Skin Tests | 1 | 2013 | 101 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2014 | 149 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 510 | 0.020 |
Why?
| | Hawaii | 1 | 2012 | 34 | 0.020 |
Why?
| | Th2 Cells | 1 | 2014 | 176 | 0.020 |
Why?
| | Genome, Mitochondrial | 1 | 2012 | 27 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2224 | 0.020 |
Why?
| | HLA Antigens | 1 | 2014 | 240 | 0.020 |
Why?
| | Income | 1 | 2013 | 202 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 59 | 0.020 |
Why?
| | Markov Chains | 1 | 2012 | 126 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 436 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 186 | 0.020 |
Why?
| | Boston | 1 | 2011 | 91 | 0.020 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 19 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 399 | 0.020 |
Why?
| | Insurance, Health | 1 | 2013 | 283 | 0.020 |
Why?
| | Angola | 1 | 2011 | 1 | 0.020 |
Why?
| | Canada | 1 | 2012 | 418 | 0.020 |
Why?
| | Mozambique | 1 | 2011 | 7 | 0.020 |
Why?
| | Air Pollutants | 1 | 2016 | 430 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 470 | 0.020 |
Why?
| | Africa South of the Sahara | 1 | 2011 | 48 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2012 | 133 | 0.020 |
Why?
| | North America | 1 | 2011 | 313 | 0.020 |
Why?
| | Culture | 1 | 2011 | 128 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 431 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 307 | 0.020 |
Why?
| | Allergens | 1 | 2013 | 409 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2011 | 195 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6763 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 816 | 0.020 |
Why?
| | Family | 1 | 2013 | 671 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 58 | 0.020 |
Why?
| | Social Behavior | 1 | 2011 | 287 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2074 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2011 | 257 | 0.020 |
Why?
| | Inbreeding | 1 | 2007 | 18 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 849 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1276 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1502 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3412 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1719 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 597 | 0.020 |
Why?
| | Reproduction | 1 | 2007 | 204 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1783 | 0.020 |
Why?
| | Smoking | 1 | 2012 | 1627 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2828 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2002 | 30 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2002 | 41 | 0.010 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2002 | 37 | 0.010 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2002 | 45 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5778 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 321 | 0.010 |
Why?
| | Mice | 1 | 2013 | 17787 | 0.010 |
Why?
|
|
Gignoux's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|